Transfusion burden reduction, TEAEs, and RBC-TI ≥16 weeks. Rates of ≥50% and ≥75% reduction in RBC transfusion burden from baseline over ≥24 weeks during the entire treatment phase, overall, and by transfusion burden (A). Summary of TEAEs during the entire treatment period (B). Rates of RBC-TI ≥16 weeks during weeks 1 to 48. Data are n (%). Transfusion events and TEAEs are reported during weeks 1 to 48. ∗Those occurring in ≥10% in any group. CI, confidence interval; TEAE, treatment emergent.